Oricell Therapeutics says its GPC3-targeted autologous CAR T, Ori-C101, is entering a confirmatory registration-directed Phase 2 trial in patients with GPC3-positive advanced hepatocellular carcinoma. The program positions Ori-C101 as the first GPC3-directed immune cell therapy—and, as stated by the company, the first CAR T for liver cancer to reach the pivotal-stage confirmatory phase. This milestone matters for CAR T development outside hematologic indications, where manufacturing complexity, patient selection, and target biology have constrained registrational progress. A confirmatory Phase 2 effort is designed to strengthen the package for potential regulatory submissions if endpoints support confirmatory efficacy. The advancement also intensifies competition among engineered-cell therapies targeting solid-tumor antigens where tumor accessibility and persistence remain critical determinants of outcomes.